Business, energy, technology, markets and global industry news from Business News Today

CAR-T therapy

PharmaDeviceNews CAR-T therapy
Representative image: Cancer immunotherapy research advances as Anixa Biosciences evaluates its breast cancer vaccine and lira-cel CAR-T therapy in early-stage clinical trials.
Pharma & Biotech

Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit?

Anixa Biosciences has presented completed Phase 1 data for its alpha-lactalbumin breast cancer vaccine and updated survival observations for liraltagene autoleucel in recurrent ovarian cancer. The findings strengthen the biological rationale behind both programmes, but controlled efficacy evidence, biomarker clarity and successful dose optimisation remain essential before either platform can be considered clinically validated.

Read More
Representative image of researchers working in a modern cell therapy laboratory, reflecting T-CURX’s acquisition of Pantherna Therapeutics and the growing race to advance in vivo CAR-T, mRNA delivery and lipid nanoparticle technologies.
Pharma & Biotech

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Read More
Representative image of liver cancer research and CAR-T therapy development, reflecting growing industry interest in Oricell’s Ori-C101 data for late-line hepatocellular carcinoma.
Pharma & Biotech

Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight

Find out how Oricell’s Ori-C101 CAR-T data could reshape expectations for late-line liver cancer treatment after ASCO 2026.

Read More
Pharma & Biotech

What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand

Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.

Read More
Pharma & Biotech

How Imviva Biotech is positioning allogeneic CAR-T therapy for autoimmune disease disruption

Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.

Read More
Pharma & Biotech

Tempest Therapeutics, Inc. bets on dual-targeting CAR-T to address antigen escape challenges

Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.

Read More
Pharma & Biotech

What Tempest Therapeutics, Inc.’s CAR-T strategy reveals about the next phase of cell therapy competition

Find out how Tempest Therapeutics, Inc.’s CAR-T strategy could shape the next phase of cell therapy competition and multiple myeloma innovation.

Read More
Pharma & Biotech

Why Gilead’s Arcellx acquisition approval could reshape the multiple myeloma CAR-T race

Gilead has cleared regulatory hurdles for Arcellx. Read why the anito-cel takeover could reshape the multiple myeloma CAR-T market.

Read More
Pharma & Biotech

Why AvenCell Therapeutics is using AVC-203 to test whether allogeneic CAR-T can move beyond manufacturing bottlenecks

AvenCell Therapeutics has dosed the first AVC-203 patient in QUADvance. Read what this means for allogeneic CAR-T and B-cell cancer treatment.

Read More
Pharma & Biotech

What AstraZeneca’s C-CAR031 deal reveals about the future of CAR-T in liver cancer

AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.

Read More